Wednesday, May 13, 2009

Jew POS Rumsfeld Making BILLIONS From Swine Flu Vaccine

This is copy protected site but worths to read

In brief: Rumsfeld is responsible for spreading viruses world wide, to find a market for his companies to gain. OR.. RUMSFELD HAS THE FULL AUTHORIZATION TO CERTIFY ANY MEDICINE THAT HE WILL EARN MONEY OUT OF..


Rumsfeld is a share holder in Gelad company that is now selling the only Vacine against the pigs / Swine / disease. ( The current world wide panicic disease)

Donald H. Rumsfeld Named Chairman of Gilead Sciences

Foster City, CA -- January 3, 1997

Gilead Sciences Inc. (Nasdaq: GILD) today announced that board member Donald H. Rumsfeld will assume the position of Chairman, effective immediately. Mr. Rumsfeld succeeds Michael L. Riordan, M.D., who founded Gilead in 1987 and has served as Chairman since 1993. Dr. Riordan will continue to serve as a director on the board.

"Gilead is fortunate to have had Don Rumsfeld as a stalwart board member since the company's earliest days, and we are very pleased that he has accepted the Chairmanship," Dr. Riordan said. "He has played an important role in helping to build and steer the company. His broad experience in leadership positions in both industry and government will serve us well as Gilead continues to build its commercial presence."

"In my years with Gilead, I have witnessed the evolution of one of the industry's premier biotechnology companies," Mr. Rumsfeld said. "Michael Riordan's founding vision and enormous accomplishments are evident in the VISTIDE® product approval, deep pipeline and talented team that will continue to move Gilead to develop novel treatments for viral diseases."

Mr. Rumsfeld, who joined Gilead as a director in 1988, is currently in private business and is distinguished for his accomplishments in both industry and government. Mr. Rumsfeld served as chief executive officer of G.D. Searle, a worldwide pharmaceutical company, from 1977 to 1985. During this time, his stewardship of Searle earned him awards as the Outstanding Chief Executive Officer in the pharmaceutical industry in 1980 and 1981. He also served as chairman and chief executive of General Instrument Corporation, a diversified electronics company and world leader in broadband and all digital high definition television technology.

A graduate of Princeton University, Mr. Rumsfeld has served in numerous positions of public service, including four terms in the U.S. Congress, U.S. Ambassador to NATO, White House Chief of Staff and as the 13th Secretary of Defense. In 1977, Mr. Rumsfeld was awarded the nation's highest civilian award, the Presidential Medal of Freedom.

In addition to Gilead, Mr. Rumsfeld presently serves as an advisor to several companies and as a member of the board of directors of ABB AB; Gulfstream Aerospace Corp.; Kellogg; Metricom, Inc.; Sears, Roebuck and Co. and Tribune Company. Mr. Rumsfeld's current civic activities include service on the board of trustees of the Eisenhower Exchange Fellowship, Freedom House and the RAND Corporation.

Dr. Riordan will continue to assist the company with strategic direction through his involvement on the board of directors. Since founding the company in 1987, Riordan has overseen Gilead's evolution to a leading biotechnology company with its first approved product and a diversified pipeline of antiviral therapies.

"Michael Riordan's vision and leadership have guided Gilead from a start-up to a commercial company, and we are pleased to rely on his continued counsel as an active board member," John C. Martin, Ph.D., President and Chief Executive Officer of Gilead said. "Over the past several years, I have enjoyed working with Don Rumsfeld as an active director and look forward to his new role as Chairman as we continue to build the Gilead business."

Gilead Sciences is a leader in the discovery and development of a new class of human therapeutics based on nucleotides, the building blocks of DNA and RNA. In 1996, Gilead's first product, VISTIDE (cidofovir injection), was cleared by the U.S. Food & Drug Administration for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. Gilead has other nucleotide product candidates in human testing for the potential treatment of viral diseases caused by CMV, human immunodeficiency virus (HIV), hepatitis B virus, herpes simplex virus and human papillomavirus.

The Company's research and development efforts encompass three interrelated programs: small molecule antivirals, cardiovascular therapeutics and genetic code blockers for cancer and other diseases. Gilead's expertise in each of these areas has also resulted in the discovery and development of non-nucleotide product candidates, including neuraminidase inhibitors for the potential treatment and prevention of viral influenza and protease inhibitors for the potential treatment of HIV.
  1. Forwarded email asserts a conspiratorial connection between the worldwide alarm over a possible flu pandemic and Donald Rumsfeld's financial interest in the company ... - Cached

Who Will Profit from the Deadly Flu This Time?
Rumsfeld made the most profit from swine flu in 1976 and bird flu in 2005. Potential profiteers of swine flu are Kleiner Perkins or Baxter.


And now from AL JAZEERA TV:
That Rumsfeld again is the man who is behind the spread of the pig virus to sell his company's medicine ( and to kill Obama in New Mexico which failed S1000+)

As the virus is spreading, the media have began speculating that it had been created in a laboratory as a biological weapon. A UN scientist is convinced that the swine flu virus, A-H1N1, and Ebola and HIV viruses were in fact manufactured biological weapons.

A month ago, the Austrian subsidiary of the American pharmaceutical company Baxter “accidentally” sent a bird flu virus to laboratories in neighbouring countries, which proves that a virus can in fact “escape” from a lab.

Keeping this in mind, it is completely logical that very few people will believe that vials containing the swine flu virus accidentally exploded in a passenger train in Switzerland during which one person was injured. But scientists claim that that type of virus is not hazardous to humans.

A reporter from Jakarta claims that WHO leaders are worried that the current swine flu virus has been genetically modified to be transmitted from one species to another because of the fact that the A-H1N1 virus contains the genetic material of the H5N1 virus, that is, bird flu.

Virus of Profiteering: Rumsfeld and Tamiflu

The money allotted to Chiron and Sanofi Pasteur is only part of the $1.2 billion in discretionary funding granted by Congress to President George W. Bush for the production of 20 million doses of pre-pandemic vaccine, which is, in turn, only part of the $.7.1 billion in avian flu emergency funds, all of which is to be spent at Bush's own discretion. That package also includes $2 billion to stockpile advanced antiviral drugs for the treatment of people already infected or exposed, the best known of which is Tamiflu, manufactured by the Swiss pharmaceutical corporation Roche. Tamiflu, whose generic name is oseltamavir, is a DNA-like compound that combines with and "clogs up" an enzyme essential to the reproduction of the flu virus and thereby stops the germ's transmission from cell to cell. Roche leases the patent for Tamiflu from Gilead Sciences, a research and development firm in Foster City, CA, specializing in "small-molecule therapeutics" including antivirals such as Viread, used in AIDS therapy, and Hepsera, used in the treatment of hepatitis B, as well as Tamiflu. From 1997 until the beginning of 2001, when he was tapped by President Bush for the job of Secretary of Defense, Donald H, Rumsfeld served as chairman of the board of Gilead Sciences.

Instead of entrusting our health and our future to Donald Rumsfeld or Bill Frist, perhaps we need to be improving our diets and getting rid of war and mass displacements, the scourges of the twentieth century which are showing so sign of abatement in the twenty-first.

No comments:

Post a Comment